Challenges for Biomarkers in Cancer Detection

Abstract: Cancer remains the leading cause of death in the United States. Biomarkers can be used to detect cancer in different stages, initiation, development, and progression. The desirable property and utility of a biomarker lie in its ability to provide an early indication of disease progression. Biomarkers should be easy to detect, measurable across populations, and useful for detection of cancer at an early stage, identification of high‐risk individuals, detection of recurrence, or monitoring endpoints in intervention studies. Recent technological advances have helped develop noninvasive, sensitive, and specific biomarkers to detect cancer at early stages of the disease.

[1]  R. Hayes,et al.  Early Detection and Risk Assessment Proceedings and Recommendations from the Workshop on Epigenetics in Cancer Prevention , 2003, Annals of the New York Academy of Sciences.

[2]  J. Califano,et al.  Progression of microsatellite instability from premalignant lesions to tumors of the head and neck , 2002, International journal of cancer.

[3]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[4]  M. Bittner,et al.  Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. , 2002, The American journal of pathology.

[5]  Ruth Etzioni,et al.  Early detection: The case for early detection , 2003, Nature Reviews Cancer.

[6]  M. Verma,et al.  Epigenetics in cancer: implications for early detection and prevention. , 2002, The Lancet. Oncology.

[7]  S. Gygi,et al.  Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry , 2003 .

[8]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[9]  S. Hanash,et al.  Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. , 2001, Cancer research.

[10]  M. Verma,et al.  New cancer biomarkers deriving from NCI early detection research. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[11]  D. Ahlquist,et al.  Stool screening for colorectal cancer: evolution from occult blood to molecular markers. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[12]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[13]  J. Marrero,et al.  Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients , 2003, Hepatology.

[14]  S. Groshen,et al.  Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[15]  Keishi Yamashita,et al.  High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. , 2003, Cancer research.

[16]  Niall O'Higgins,et al.  Mammaglobin a: a promising marker for breast cancer. , 2002, Clinical chemistry.

[17]  Mukesh Verma,et al.  Proteomic analysis of cancer-cell mitochondria , 2003, Nature Reviews Cancer.